Skip to main content

Table 2 Summary of clinical trials targeting CD47 with SIRPα-Fc fusion protein

From: Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed

SIRPα-Fc fusion Company IgG Indications Monotherapy or Combination Phage stage Clinical trials NO. Status
Evorpacept
(ALX148)
Alex
Therapeutic
mutated SIRPα-Fc IgG1 Metastatic Cancer, Solid Tumor, Advanced Cancer, NHL monotherapy, Pembrolizumab, Trastuzumab, rituximab, Pembrolizumab+ 5-FU + Cisplatin, Trastuzumab+Ramucirumab+Paclitaxel Phase I NCT03013218 174 participants,
Active, not recruiting
Higher Risk Myelodysplastic Syndrome Azacitidine Phase I NCT04417517 173 participants,
Recruiting
HNSCC Pembrolizumab Phase II NCT04675294 183 participants,
Recruiting
HNSCC Pembrolizumab+Cisplatin/Carboplatin+5FU Phase II NCT04675333 168 participants,
AML Venetoclax, Azacitidine Phase I/II NCT04755244 97 participants,
Recruiting
HER2+ gastric cancer Trastuzumab, Ramucirumab, Paclitaxel Phase II/III NCT05002127 450 participants,
Recruiting
Indolent and Aggressive B-Cell Non-Hodgkin Lymphoma Lenalidomide+Rituximab Phase I/II NCT05025800 52 participants, Recruiting
HER2+ gastric cancer Zanidatamab Phase Ib/II NCT05027139 93 participants, Recruiting
Microsatellite Stable Metastatic Colorectal Cancer Cetuximab+Pembrolizumab Phase II NCT05167409 80 participants, Not yet recruiting
TTI-621 Trillium
Therapeutics
SIRPα-Fc
IgG1
Hematologic Malignancies and Selected Solid Tumors monotherapy, Rituximab and Nivolumab Phase I NCT02663518 260 participants,
Recruiting
R/R Solid Tumors and Mycosis Fungoides monotherapy, PD-1/PD-L1 Inhibitor, pegylated interferon-α2a, T-Vec, radiation Phase I NCT02890368 56 participants,
terrminated
Leiomyosarcoma Doxorubicin Phase I/II NCT04996004 80 participants,
Recruiting
Multiple Myeloma Daratumumab Hyaluronidase-fihj Phase I NCT05139225 40 participants,
Recruiting
TTI-622 SIRPα-Fc
IgG4
Lymphoma, myeloma monotherapy, Rituximab, PD-1 Inhibitor, Proteasome-inhibitor Regimen Phase I NCT03530683 150 participants,
Recruiting
Multiple Myeloma Daratumumab Hyaluronidase-fihj Phase I NCT05139225 40 participants,
Recruiting
Platinum-Resistant Ovarian Cancer Pegylated Liposomal Doxorubicin Phase I/II NCT05261490 50 participants,
Recruiting
IMM01 ImmunoOnco mutated SIRPα-Fc IgG1 AML, MDS Azacitidine Phase I/II NCT05140811 76 participants,
Not yet recruiting